AI generates compounds with experimentally validated pancreatic cancer cell selectivity
The IRB Barcelona team trained cell-line cytotoxicity predictors on data from more than 11,000 compounds assayed across pancreatic-cancer and control cell lines, then integrated the models with a reinforcement-learning generative system to design molecules for cell-selective effects. In follow-up tests, 45 AI-designed molecules or close analogues were assayed; 20 showed the intended cell-specific cytotoxicity, and dose-response testing confirmed 18 of those 20. Across the seven selectivity exercises, at least one hit was found in five; measured IC50 values could be calculated for 12 confirmed hits and ranged from 0.97 to 16.6 μM in the targeted cell lines.
Technology: Cell-line-specific cytotoxicity prediction models coupled to a reinforcement-learning molecular generator (REINVENT-based workflow)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The IRB Barcelona team trained cell-line cytotoxicity predictors on data from more than 11,000 compounds assayed across pancreatic-cancer and control cell lines, then integrated the models with a reinforcement-learning generative system to design molecules for cell-selective effects.
- Still unknown: This is a proof-of-concept hit-discovery study using in-vitro cell-line assays, not evidence of tumor selectivity in patients or an animal efficacy result. Only binary cytotoxicity labels at 10 μM informed the predictors; 45 generated structures or close analogues were tested, with 20 showing desired phenotypes and 18 confirming in dose-response assays. Exact generated structures were not always the synthesized compounds, and measured IC50 spans 0.97–16.6 μM for 12 of the confirmed hits. The paper explicitly characterizes this as an early hit-discovery stage.
- AI role: The authors trained predictive models on phenotypic screening data from >11,000 compounds, then used their scores as rewards/objectives in a generative workflow to propose molecules intended to kill one pancreatic-cancer cell line while sparing another or control cells. Candidate molecules or close purchasable analogues were experimentally tested and dose-response validated.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42162204/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.